AstraZeneca/GSK/University of Cambridge collaborate to support UK national effort to boost COVID-19 testing
As part of the UK Government’s announcement of a new five pillar plan to boost testing for COVID-19, AstraZeneca, GSK and the University of Cambridge have formed a joint collaboration to take action to support this national effort.
A new testing laboratory will be set up by AstraZeneca, GSK and Cambridge at the University’s Anne McLaren Building. This facility will be used for high throughput screening for COVID-19 testing and to explore the use of alternative chemical reagents for test kits in order to help overcome current supply shortages.
Alongside this new testing facility, AstraZeneca and GSK are working together to provide process optimisation support to the UK national testing centres in Milton Keynes, Alderley Park and Glasgow for COVID-19, providing expertise in automation and robotics to help the national testing system to continue to expand capacity over the coming weeks.
While diagnostic testing is not part of either company’s core business, we are moving as fast as we can to help where possible - with a focus on providing our world class scientific and technical expertise - working both with the Government’s screening programme and alongside the wider life sciences sector and specialist diagnostic companies.
Further updates on progress will be issued on this work in due course.